Marshall Wace’s Acceleron Pharma XLRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-12,096
Closed -$2.08M 4550
2021
Q3
$2.08M Buy
+12,096
New +$1.58M 0.01% 1511
2021
Q2
Sell
-6,542
Closed -$887K 3447
2021
Q1
$887K Buy
6,542
+1,023
+19% +$132K ﹤0.01% 1724
2020
Q4
$706K Buy
+5,519
New +$647K ﹤0.01% 1346
2020
Q3
Sell
-3,162
Closed -$301K 2051
2020
Q2
$301K Buy
3,162
+1,539
+95% +$148K ﹤0.01% 1331
2020
Q1
$146K Buy
+1,623
New +$126K ﹤0.01% 1252
2019
Q2
Sell
-208,333
Closed -$9.7M 2013
2019
Q1
$9.7M Buy
208,333
+207,304
+20,146% +$9.1M 0.09% 268
2018
Q4
$45K Buy
+1,029
New +$51.4K ﹤0.01% 1458
2016
Q4
Sell
-15,684
Closed -$568K 1173
2016
Q3
$568K Buy
+15,684
New +$520K ﹤0.01% 793

Marshall Wace's XLRN Position: Q4 2021 in Review

Marshall Wace sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 12,096 shares — an estimated $2.08M sold.

Marshall Wace first reported a position in XLRN in Q3 2016 and held it in 8 quarters. The position peaked at $9.7M in Q1 2019. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Marshall Wace reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 12,096 Acceleron Pharma shares in Q4 2021, an estimated $2.08M.
  • Marshall Wace first reported a position in Acceleron Pharma in Q3 2016 and held it in 8 quarters.
  • Marshall Wace's Acceleron Pharma position peaked at $9.7M in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.